



PROF. ROBERTO POLA (Orcid ID : 0000-0001-5224-2931)

Article type : Brief Report

## **Incidence of Deep Vein Thrombosis among non-ICU Patients Hospitalized for COVID-19 Despite Pharmacological Thromboprophylaxis**

Angelo Santoliquido MD\*, Angelo Porfidia MD†, Antonio Nesci MD\*,  
Giuseppe De Matteis MD†, Giuseppe Marrone MD‡, Enrica Porceddu MD‡,  
Giulia Cammà MD‡, Igor Giarretta MD‡, Massimo Fantoni§, Francesco Landi¶,  
Antonio Gasbarrini‡, Roberto Pola MD\*

\* *Department of Cardiovascular Sciences, † Division of Internal Medicine,*  
‡ *Department of Medical and Surgical Sciences, § Division of Infectious Diseases,*  
¶ *Division of Geriatrics, Fondazione Policlinico Universitario A. Gemelli IRCCS,*  
*Università Cattolica del Sacro Cuore School of Medicine, Rome, Italy*

on behalf of the **GEMELLI AGAINST COVID-19 Group\***

**Running head:** Deep Vein Thrombosis in COVID-19 Patients

**Correspondence to:**

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/JTH.14992](#)

This article is protected by copyright. All rights reserved

Prof. Roberto Pola, MD PhD

Istituto di Medicina Interna e Geriatria

9th floor, C wing, room C907

Policlinico A. Gemelli

Lgo. A. Gemelli 8

00168 Rome, Italy

Tel: +39-06-30157075

Email: [roberto.pola@unicatt.it](mailto:roberto.pola@unicatt.it)

\* **GEMELLI AGAINST COVID-19 Group:** Valeria Abbate, Nicola Acampora, Giovanni Addolorato, Fabiana Agostini, Maria E. Ainora, Elena Amato, Gloria Andriollo, Brigida E. Annicchiarico, Mariangela Antonelli, Gabriele Antonucci, Armuzzi Alessandro, Christian Barillaro, Fabiana Barone, Rocco D. A. Bellantone, Andrea Bellieni, Andrea Benicchi, Francesca Benvenuto, Filippo Berloco, Roberto Bernabei, Antonio Bianchi, Luigi M. Biasucci, Stefano Bibbò, Federico Biscetti, Nicola Bonadia, Alberto Borghetti, Giulia Bosco, Silvia Bosello, Vincenzo Bove, Giulia Bramato, Vincenzo Brandi, Dario Bruno, Maria C. Bungaro, Alessandro Buonomo, Livia Burzo, Angelo Calabrese, Andrea Cambieri, Giulia Cammà, Marcello Candelli, Gennaro Capalbo, Lorenzo Capaldi, Esmeralda Capristo, Luigi Carbone, Silvia Cardone, Angelo Carfi, Annamaria Carnicelli, Cristiano Caruso, Francesco A. Casciaro, Lucio Catalano, Roberto Cauda, Andrea L. Cecchini, Lucia Cerrito, Michele Ciaburri, Rossella Cianci, Sara Cicchinelli, Arturo Ciccullo, Francesca Ciciarello, Antonella Cingolani, Maria C. Cipriani, Gaetano Coppola, Andrea Corsello, Federico Costante, Marcello Covino, Stefano D'Addio, Alessia D'Alessandro, Maria E. D'Alfonso, Emanuela D'Angelo, Francesca D'Aversa, Fernando Damiano, Tommaso De Cunzo, Giuseppe De Matteis, Martina De Siena, Francesco De Vito, Valeria Del Gatto, Paola Del Giacomo, Fabio Del Zompo, Davide Della Polla, Luca Di Gialleonardo, Simona Di Giambenedetto, Roberta Di Luca, Luca Di Maurizio, Alex Dusina, Alessandra Esperide, Domenico Faliero, Cinzia Falsiroli, Massimo Fantoni, Annalaura Fedele, Daniela Feliciani, Andrea Flex, Evelina Forte, Francesco Franceschi, Laura Franza, Barbara Funaro, Mariella Fuorlo, Domenico Fusco, Maurizio Gabrielli, Eleonora Gaetani, Antonella Gallo, Giovanni Gambassi, Matteo Garcovich, Antonio Gasbarrini, Irene Gasparrini, Silvia Gelli, Antonella Giampietro, Laura Gigante, Gabriele Giuliano, Giorgia Giuliano, Bianca Giupponi, Elisa Gremese, Caterina Guidone, Amerigo Iaconelli, Angela Iaquinta, Michele Impagnatiello, Riccardo Inchingolo, Raffaele Iorio, Immacolata M. Izzi, Cristina Kadhim, Daniele I. La Milia, Francesco Landi, Giovanni Landi, Rosario Landi, Massimo Leo, Antonio Liguori, Rosa Liperoti, Marco M. Lizzio, Maria R. Lo Monaco, Pietro Locantore, Francesco Lombardi, Loris Lopetuso, Valentina Loria, Angela R. Losito, Andrea Lupascu, Noemi Macerola, Giuseppe Maiuro, Francesco Mancarella, Francesca Mangiola, Alberto Manno, Debora Marchesini, Giuseppe Marrone, Ilaria Martis, Anna M. Martone, Emanuele Marzetti, Maria V. Matteo, Luca Miele, Alessio Migneco, Irene Mignini, Alessandro Milani, Domenico Milardi, Massimo Montalto, Flavia Monti, Davide Moschese, Barbara P. L. Mothaenje, Celeste A. Murace, Rita Murri, Marco Napoli, Elisabetta Nardella, Gerlando Natalello, Simone M. Navarra, Antonio Nesci, Alberto Nicoletti, Tommaso

Nicoletti, Rebecca Nicolò, Nicola Nicolotti, Enrico C. Nista, Eugenia Nuzzo, Veronica Ojetti, Francesco C. Pagano, Cristina Pais, Alfredo Papa, Luigi G. Papparella, Mattia Paratore, Giovanni Pecorini, Simone Perniola, Erika Pero, Giuseppe Perrinello, Luca Petricca, Martina Petrucci, Chiara Picarelli, Andrea Piccioni, Giulia Pignataro, Raffaele Pignataro, Marco Pizzoferrato, Fabrizio Pizzolante, Roberto Pola, Caterina Policola, Maurizio Pompili, Valerio Pontecorvi, Francesca Ponziani, Valentina Popolla, Enrica Porceddu, Angelo Porfidia, Giuseppe Privitera, Gabriele Pulcini, Simona Racco, Francesca Raffaelli, Gian L. Rapaccini, Luca Richeldi, Emanuele Rinninella, Sara Rocchi, Stefano Romano, Federico Rosa, Laura Rossi, Raimondo Rossi, Enrica Rossini, Elisabetta Rota, Fabiana Rovedi, Gabriele Rumi, Andrea Russo, Luca Sabia, Andrea Salerno, Sara Salini, Lucia Salvatore, Dehara Samori, Maurizio Sanguinetti, Luca Santarelli, Paolo Santini, Angelo Santoliquido, Francesco Santopaulo, Michele C. Santoro, Francesco Sardeo, Caterina Sarnari, Luisa Saviano, Tommaso Schepis, Francesca Schiavello, Giancarlo Scoppettuolo, Luisa Sestito, Carlo Settanni, Valentina Siciliano, Benedetta Simeoni, Andrea Smargiassi, Domenico Staiti, Leonardo Stella, Eleonora Taddei, Rossella Talerico, Enrica Tamburrini, Claudia Tarli, Pietro Tilli, Enrico Torelli, Matteo Tosato, Alberto Tosoni, Luca Tricoli, Marcello Tritto, Mario Tumbarello, Anita M. Tummolo, Federico Valletta, Giulio Ventura, Lucrezia Verardi, Lorenzo Vetrone, Giuseppe Vetrugno, Elena Visconti, Raffaella Zaccaria, Lorenzo Zelano, Lorenzo Zileri Dal Verme, Giuseppe Zuccalà.

## Essentials

- The incidence of deep vein thrombosis (DVT) among patients hospitalized for COVID-19 is unknown.
- A screening for DVT was performed in COVID-19 patients that were receiving thromboprophylaxis.
- The incidence of DVT was 11.9% (95% CI 4.98–18.82). Most DVTs were asymptomatic.
- DVT may occur in COVID-19 patients despite guideline-recommended thromboprophylaxis.

## Abstract

**Background:** A remarkably high incidence of VTE has been reported among critically ill patients with COVID-19 assisted in the Intensive Care Unit (ICU). However, VTE burden among non-ICU patients hospitalized for COVID-19 that receive guideline-recommended thromboprophylaxis is unknown.

**Objectives:** To determine the incidence of VTE among non-ICU patients hospitalized for COVID-19 that receive pharmacological thromboprophylaxis.

**Methods:** We performed a systematic screening for the diagnosis of deep vein thrombosis (DVT) by lower limb vein compression ultrasonography (CUS) in consecutive non-ICU patients hospitalized for COVID-19, independently of the presence of signs or symptoms of DVT. All patients were receiving pharmacological thromboprophylaxis with either enoxaparin or fondaparinux.

**Results:** The population that we screened consisted of 84 consecutive patients, with a mean age of  $67.6 \pm 13.5$  years and a mean Padua Prediction Score of  $5.1 \pm 1.6$ . Seventy-two patients (85.7%) had respiratory insufficiency, required oxygen supplementation, and had reduced mobility or were bedridden. In this cohort, we found 10 cases of DVT, with an incidence of 11.9% (95% CI 4.98–18.82). Of these, 2 were proximal DVT (incidence rate 2.4%, 95% CI -0.87–5.67) and 8 were distal DVT (incidence rate 9.5%, 95% CI 3.23–5.77). Significant differences between subjects with and without DVT were D-dimer  $>3,000 \mu\text{g/L}$  ( $P < 0.05$ ), current or previous cancer ( $P < 0.05$ ), and need of high flow nasal oxygen therapy and/or non-invasive ventilation ( $P < 0.01$ ).

**Conclusions:** DVT may occur among non-ICU patients hospitalized for COVID-19, despite guideline-recommended thromboprophylaxis.

**Keywords:** COVID-19; deep vein thrombosis; venous thromboembolism; thromboprophylaxis

## Introduction

Since the beginning of 2020, the infectious disease caused by coronavirus 2 (SARS-CoV-2), named COVID-19, has spread around the world becoming a global emergency [1,2]. In the last

few months there has been increasing appreciation that venous thromboembolism (VTE) might contribute to acute respiratory failure in COVID-19 patients and affect clinical outcome. Indeed, subjects hospitalized for COVID-19 are the prototypical example of acutely ill medical patients at increased risk of VTE, as they suffer from an acute infection, may have acute respiratory failure, and often are bedridden, or have reduced mobility, since they need oxygen supplementation and/or are isolated in their room due to hospital restrictions. The concomitant presence of these conditions substantially increases the risk of VTE, and this risk may be even higher if other factors, such as cancer, history of previous VTE, and age  $\geq 70$  years, exist [3]. In addition, some COVID-19 patients may have significant abnormalities of coagulation parameters, including D-dimer levels above  $>1,000 \mu\text{g/L}$  [4], and this further supports the concept that VTE needs to be properly prevented in these patients.

A remarkably high incidence of VTE has been recently reported among COVID-19 patients assisted in the Intensive Care Unit (ICU), although all patients were receiving at least thromboprophylactic doses of anticoagulants [5,6]. Also, there are autopsy data indicating that deep vein thrombosis (DVT), pulmonary embolism (PE), and various types of microvascular pathology may be found in patients deceased for COVID-19, although such findings have not been confirmed in other autopsy series [7-9]. Based on this and other anecdotal reports, many physicians are advocating the empiric use of therapeutic anticoagulation even in patients who do not have a documented diagnosis of VTE [10]. On the other hand, the current position of the majority of medical societies still is to use standard prophylactic doses of anticoagulation for hospitalized COVID-19 patients, as it is recommended for other acutely ill medical patients [11,12].

In this study, we performed a systematic screening for the diagnosis of DVT in non-ICU consecutive patients hospitalized for COVID-19 that were receiving pharmacological thromboprophylaxis.

## Methods

All the patients affected by COVID-19 and hospitalized at the 'Fondazione Policlinico Universitario A. Gemelli IRCCS' (Rome, Italy) between 3<sup>rd</sup> and 10<sup>th</sup> of April 2020 were included in the study, with the exception of those younger than 18 years, those assisted in the ICU, and those receiving full-dose anticoagulant therapy for conditions such as atrial fibrillation and/or previous VTE. All patients had an established diagnosis of infection by SARS-CoV-2, confirmed by a positive molecular assay on oral/nasopharyngeal swabs. All patients were receiving a prophylactic dose of anticoagulant (either enoxaparin 40 mg once daily or fondaparinux 2.5 mg daily) since the first day of hospitalization, in keeping with the internal guidelines of our University Hospital for the prevention of VTE.

Venous compression ultrasonography (CUS) of the legs was performed on all enrolled patients during hospital stay, using a Philips CX50 portable ultrasound system, and consisted in the assessment of the proximal and distal deep venous system of both legs. The distal veins included in the study were the posterior tibial, fibular, gastrocnemius (internal and external), and soleal veins. All venous segments were examined in real-time B-mode using colour Doppler in transverse and longitudinal views. Lack of compressibility, or direct identification of an endoluminal thrombus, were the criteria used for the diagnosis of DVT, as established in the literature [13].

Demographic data, clinical characteristics, and laboratory results were collected from the medical charts of our Hospital. Respiratory insufficiency was defined as PaO<sub>2</sub> <60 mmHg and/or PaCO<sub>2</sub> >50 mmHg in room air, or need for oxygen supplementation. Complete blood tests were available for all patients, including D-dimer levels, which were assessed by using a latex agglutination test. The Padua Prediction Score (PPS) was calculated for all patients.

Data are presented as means±standard deviation (SD), or number and percentage when appropriate. T test or Mann-Whitney U test were used to assess differences between groups of patients. P <0.05 was defined as statistically significant. Statistical analysis was conducted using SPSS software version 21.0 (IBM, Armonk, NY, USA).



The study was approved by the Ethics Committee of the 'Fondazione Policlinico Universitario A. Gemelli IRCCS' (Rome, Italy) (ID number 3149). Due to the nature of the study, the Ethics Committee waived the need for informed consent.

Accepted Article

## Results

A total of 84 hospitalized COVID-19 patients were studied. The demographic, clinical, and laboratory data of the studied population are presented in **Table 1**. The mean age was  $67.6 \pm 13.5$  years. There were 61 males (72.6%) and 23 females (27.4%). The following comorbidities were present at the time of hospital admission: hypertension in 45 patients (53.6%), type 2 diabetes mellitus in 18 patients (21.4%), obesity in 15 patients (17.9%), history of CAD and/or CVD in 11 patients (13.1%), cancer (current or previous) in 14 patients (16.7%). Three patients (3.6%) had history of previous VTE. Recent trauma and/or recent surgery were found in 8 patients (9.5%). The mean length of hospital stay of this cohort was  $24.0 \pm 13.5$  days. There were 8 deaths, with a mortality rate of 9.5%. At the time of CUS examination, 72 patients (85.7%) had respiratory insufficiency, required oxygen supplementation, had reduced mobility or were bedridden. High flow nasal oxygen therapy and/or non-invasive ventilation (NIV) was required in 15 patients (17.8%). The mean platelet count was  $266 \pm 120 \times 10^9/L$ . The mean D-dimer level was  $4,108 \pm 7,098$   $\mu g/L$ . Forty-six patients (54.8%) had D-dimer level  $>1,500$   $\mu g/L$ . Twenty-three patients (27.4%) had D-dimer level  $>3,000$   $\mu g/L$ . The mean prothrombin time (PT) was  $11.2 \pm 0.7$  seconds.

**Table 2** presents information on the PPS and the type of prophylactic anticoagulation used in the enrolled patients. It also presents the data in the incidence rate of DVT. The PPS was 4 in 44 patients (52.4%), 5 in 17 patients (20.3%) and  $>5$  in 23 patients (27.4%). The mean value of PPS was  $5.1 \pm 1.6$ . All patients (100.0%) were on anticoagulant thromboprophylaxis since the first day of hospitalization, in the majority of cases with enoxaparin and in small number of cases with fondaparinux. CUS was performed  $5.8 \pm 2.2$  days after hospital admission. In 5 cases, it was performed within the first 48 hours from hospital admission. In none of these cases a diagnosis of DVT was performed. A DVT was found in 10 patients, with an overall incidence of 11.9% (95% CI 4.98–18.82). In 8 cases, they were distal DVT (located in veins below the knee: peroneal, posterior, anterior tibial, and muscular veins), with an incidence rate of 9.5% (95% CI 3.23–15.77). There were 2 proximal DVT, with an incidence rate of 2.4% (95% CI -0.87–5.67). In 4 cases, DVT was bilateral. Signs or symptoms of DVT (such as pain, swelling, warmth, redness, cramps, bluish or whitish skin discoloration at the level of the lower limb) were present only in 2 of the 10 patients with DVT.

Subjects with DVT did not differ from those without DVT in terms of age, sex, and frequency of obesity, hypertension, type 2 diabetes mellitus, and CAD/CVD. Also, their PPS was

similar to that displayed by subjects without DVT. Likewise, mean D-dimer levels, PT, and platelet count were similar between the two groups. However, the number of subjects with D-dimer level  $>3,000 \mu\text{g/L}$  was significantly higher in the DVT group than in the non-DVT group ( $P<0.05$ ). In addition, subjects with DVT had higher incidence of cancer (either current or previous) (40.0% vs 13.5%,  $P<0.05$ ) and more frequently required high flow nasal oxygen therapy and/or NIV, compared with subjects without DVT (60.0% vs 8.1%,  $P<0.01$ ). These data are summarized in **Table 3**.

## Discussion

This study provides information on the incidence of DVT among non-ICU patients hospitalized for COVID-19 that receive guideline-recommended thromboprophylaxis. We found 10 cases of DVT among the 84 patients included in the study, with an overall incidence of 11.9%. Our findings are consistent with those of Demelo-Rodriguez and coll., who recently reported an incidence of DVT of 14.7% among 156 patients hospitalized in non-intensive care units with diagnosis of COVID-19 pneumonia [14]. The incidence of DVT that we found is high, compared with the results of the randomized double-blind MEDENOX trial, which is the landmark study that assessed the incidence of DVT among acutely ill hospitalized medical patients receiving pharmacological thromboprophylaxis. Indeed, in the MEDENOX Study, 16 DVT were found among 291 patients treated with enoxaparin, with an incidence of 5.5% [15]. However, it is important to point out that the increased incidence of DVT that we found in our study was mainly due to a relatively high number of distal DVT, while the incidence of proximal DVT was not substantially different from that observed in the MEDENOX trial. In particular, the incidence of distal DVT in our study and in the MEDENOX trial was 9.5% and 3.8%, respectively, while the incidence of proximal DVT in our study was 2.4% and in the MEDENOX study was 1.7%. Nonetheless, it should be noted that in the MEDENOX study the diagnosis of DVT was done by venography, while we used CUS, which is known to have lower sensitivity for the diagnosis of DVT in asymptomatic patients [16,17]. Therefore, it is possible to hypothesize that in our study the number of COVID-19 patients with DVT could have been higher if venography had been used. Another important randomized placebo-controlled study that assessed the incidence of DVT among acutely ill hospitalized medical patients receiving pharmacological thromboprophylaxis is the PREVENT trial [18]. In this study, subjects treated with dalteparin displayed a 2.7% incidence of proximal DVT, which is similar to what we found in our study. Of note, in the PREVENT trial, the diagnosis of DVT was done by CUS, as it was done in our study. A difference is that distal DVT were not assessed in the PREVENT trial, based on the concept that their clinical relevance is not well established. We decided instead to search for distal DVT, because we believe that the risk of extension of thrombosis to proximal veins may be high in COVID-19 patients. Whether the incidence of DVT is higher in COVID-19 patients than in subjects affected by other acute viral respiratory infections remains to be determined. Indeed, high rates of thrombotic complications

have been reported also during the H1N1 influenza virus pandemic and the various outbreaks of SARS-CoV infection [19-23].

Of note, the patients that had DVT in our study did not differ from those without DVT in terms of age, male sex, and comorbidities. Also mean PPS, D-dimer levels, PT, and platelet count were similar between patients with and without DVT. There were though some statistically significant differences. One was that patients with DVT had more often D-dimer levels  $>3,000$   $\mu\text{g/L}$ , compared with subjects without DVT. This is interesting, because a D-dimer cut-off value of  $3,000$   $\mu\text{g/L}$  has been recently associated with mortality in non-ICU COVID-19 patients treated with heparin [24]. Instead, we did not find a difference between DVT and non-DVT patients when subjects with D-dimer level  $>1,500$   $\mu\text{g/L}$  were considered, although this D-dimer value has been recently proposed as cut-off to predict thrombosis in COVID-19 patients assisted in the ICU [25].

Our study has some limitations. First, the number of patients is relatively small and therefore our findings need to be confirmed in larger samples. Second, CUS was performed relatively early during hospitalization and not at the same time-point for all patients, therefore it is possible that DVT that developed at later stages during hospital stay were not identified. Also, CUS was never performed at the moment of hospitalization. Therefore, we cannot exclude that some patients had developed DVT before hospitalization, when they were not still receiving anticoagulant prophylaxis. Third, we have no data on the clinical outcome of patients with DVT compared to subjects without DVT. Finally, we did not look for PE and this is an important issue that needs to be addressed by additional studies in the future.

In conclusion, our study shows that DVT is not uncommon among non-ICU patients hospitalized for COVID-19, despite the use of guideline-recommended thromboprophylaxis. The best thromboprophylactic strategy to use in COVID-19 patients remains to be determined.

### **Role and contribution of each author**

A. Santoliquido and A. Porfidia: concept and design, analysis and interpretation of data; critical writing and final approval of the version to be published.

A. Nesci, G. De Matteis, G. Marrone, E Porceddu and G. Cammà: analysis and interpretation of data; final approval of the version to be published.

I. Giarretta: analysis and/or interpretation of data; critical writing, revising the intellectual content; and final approval of the version to be published.

M. Fantoni, F. Landi and A. Gasbarrini: concept and design; critical writing or revising the intellectual content; and final approval of the version to be published.

R. Pola: concept and design, analysis and/or interpretation of data; critical writing or revising the intellectual content; and final approval of the version to be published.

### **Conflicts of interest**

The Authors have no conflicts of interest to disclose.

## References

1. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
2. Helmy YA, Fawzy M, Elasad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. *J Clin Med*. 2020;9:1225.
3. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, De Bon E, Tormene D, Pagnan A, Prandoni P. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. *J Thromb Haemost*. 2010;8:2450-2457.
4. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020; 395:1054-1062.
5. Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kantf KM, Kapteina FH, van Paassend J, Stalsa MA, Huismana MV, Endemane H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145-147.
6. Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K. High Incidence of Venous Thromboembolic Events in Anticoagulated Severe COVID-19 Patients. *J Thromb Haemost*. 2020 Apr 22;10.1111/jth.14869. doi: 10.1111/jth.14869.
7. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. *N Engl J Med*. 2020 May 21. doi: 10.1056/NEJMoa2015432.
8. Schaller T, Hirschtühl K, Burkhardt K, Braun G, Trepel M, Märkl B, Claus R. Postmortem examination of patients with COVID-19. *J Am Med Ass*. 2020 May 21;e208907. doi: 10.1001/jama.2020.8907.
9. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Brederke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-

Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. *Ann Intern Med.* 2020 May 6:M20-2003. doi: 10.7326/M20-2003.

10. Porfidia A, Pola R. Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines. *J Thromb Thrombolysis.* 2020;50:68-71.
11. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J Thromb Hemost.* 2020;18:1023-1026.
12. Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, Liu P, Elalamy I, Wang C; Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group. Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. *Thromb Haemost.* 2020;120:937-948.
13. Righini M, Le Gal G, Aujesky D, Roy P-M, Sanchez O, Verschuren F, Kossovsky M, Bressollette L, Meyer G, Perrier A, Bounameaux H. Complete venous ultrasound in outpatients with suspected pulmonary embolism. *J Thromb Haemost.* 2009;7:406-412.
14. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macías M, Toledo-Samaniego N, García-García A, García-Fernández-Bravo I, Ji Z, de-Miguel-Diez J, Álvarez-Sala-Walther LA, Del-Toro-Cervera J, Galeano-Valle F. Incidence of Asymptomatic Deep Vein Thrombosis in Patients With COVID-19 Pneumonia and Elevated D-dimer Levels. *Thromb Res.* 2020;192:23-26.
15. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. *N Engl J Med.* 1999;341:793-800.
16. Keller F, Flosbach CW, PRIME Study Group. A randomised multicentre study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. *Thromb Haemost.* 1995;73:1106.



17. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecularweight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. *Haemostasis*. 1996;26:127-139.
18. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. *Circulation*. 2004;110:874-879.
19. Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. Pandemic H1N1 Influenza Infection and Vascular Thrombosis. *Clin Infect Dis*. 2011;52:e14-17.
20. Avnon AS, Munteanu D, Smoliakov A, Jotkowitz A, Barski L. Thromboembolic Events in Patients With Severe Pandemic Influenza A/H1N1. *Eur J Intern Med*. 2015;26:596-598.
21. Agarwal PP, Cinti S, Kazerooni EA. Chest Radiographic and CT Findings in Novel Swine-Origin Influenza A (H1N1) Virus (S-OIV) Infection. *AJR Am J Roentgenol*. 2009;193:1488-1493.
22. Harms PW, Schmidt LA, Smith LB, et al. Autopsy findings in eight patients with fatal H1N1 influenza. *Am J Clin Pathol*. 2010;134:27-35.
23. Xiang-Hua Y, Le-Min W, Ai-Bin L, Zhu G, Riquan L, Xu-You Z, Wei-Wei R, Ye-Nan W. Severe acute respiratory syndrome and venous thromboembolism in multiple organs. *Am J Respir Crit Care Med*. 2010;182:436-437.
24. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020;18:1094-1099.
25. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18:1421-1424.

**Table 1.** Demographic, clinical, and laboratory characteristics of the 84 patients hospitalized for COVID-19 who underwent CUS

<b>Characteristic</b>	<b>Number (%) or mean (<math>\pm</math>SD)</b>
<i>Mean age, years <math>\pm</math> SD</i>	67.6 $\pm$ 13.5
<i>Men, n (%)</i>	61 (72.6)
<i>Obesity, n (%)</i>	15 (17.9)
<i>Hypertension, n (%)</i>	45 (53.6)
<i>Type 2 diabetes mellitus, n (%)</i>	18 (21.4)
<i>CAD and/or CVD, n (%)</i>	11 (13.1)
<i>Cancer (previous or current), n (%)</i>	14 (16.7)
<i>Previous VTE, n (%)</i>	3 (3.6)
<i>Trauma or recent surgery, n (%)</i>	8 (9.5)
<i>Acute infectious disease, n (%)</i>	84 (100.0)
<i>Reduced mobility, n (%)</i>	72 (85.7)
<i>Acute respiratory failure with oxygen supplementation, n (%)</i>	72 (85.7)
<i>High flow nasal oxygen therapy or NIV</i>	15 (17.8)
<i>Mean haemoglobin level, g/L <math>\pm</math> SD</i>	12.9 $\pm$ 13.0
<i>Mean white blood cell count, <math>10^9</math>xL <math>\pm</math> SD</i>	5831 $\pm$ 2825
<i>Mean platelet count, <math>10^9</math>xL <math>\pm</math> SD</i>	266 $\pm$ 120
<i>Mean D-dimer level, <math>\mu</math>g/L <math>\pm</math> SD</i>	4108 $\pm$ 7098
<i>- D-dimer &gt; 1,500 <math>\mu</math>g/L, n (%)</i>	46 (54.8)
<i>- D-dimer &gt; 3,000 <math>\mu</math>g/L, n (%)</i>	23 (27.4)
<i>Mean fibrinogen level, mg/dL <math>\pm</math> SD</i>	499 $\pm$ 170

<i>Mean PT, seconds <math>\pm</math> SD</i>	11.2 $\pm$ 0.7
<i>Mean length of hospital stay, days <math>\pm</math> SD</i>	24.0 $\pm$ 13.5
<i>Deaths, n (%)</i>	8 (9.5)

SD: standard deviation; CAD: coronary artery disease; CVD: cerebrovascular disease; VTE: venous thromboembolism; NIV: non-invasive ventilation; PT: prothrombin time

**Table 2.** Padua Prediction Score (PPS), type of pharmacological thromboprophylaxis, and incidence of thrombosis among patients hospitalized for COVID-19 who underwent CUS

Characteristic	Number (%) or mean (SD)
<i>PPS = 4, n (%)</i>	44 (52.4)
<i>PPS = 5, n (%)</i>	17 (20.3)
<i>PPS &gt;5, n (%)</i>	23 (27.4)
<i>PPS, mean ± SD</i>	5.1 ± 1.6
<i>Pharmacological thromboprophylaxis, n (%)</i>	84 (100.0)
- <i>enoxaparin 40 mg once daily</i>	82 (97.6)
- <i>fondaparinux 2.5 mg once daily</i>	2 (2.4)
<i>DVT, n (%), (95% CI)</i>	10 (11.9) (4.98–18.82)
- <i>proximal DVT, n (%), (95% CI)</i>	2 (2.4) (-0.87–5.67)
- <i>distal DVT, n (%), (95% CI)</i>	8 (9.5) (3.23–15.77)
- <i>bilateral DVT, n (%), (95% CI)</i>	4 (4.7) (0.17–9.23)
- <i>symptomatic DVT, n (%), (95% CI)</i>	2 (2.4) (-0.87–5.67)
<i>Mean length of hospital stay at the time of CUS, days ± SD</i>	5.8 ± 2.2

PPS: Padua prediction score; DVT: deep vein thrombosis; CUS: compression ultrasonography

**Table 3.** Comparison between subjects with and without DVT

<b>Characteristic</b>	<b>DVT (n = 10)</b>	<b>No DVT (n = 74)</b>	<b>P</b>
<i>Mean age, years ± SD</i>	72.0±11.3	67.0±13.8	n.s.
<i>Men, n (%)</i>	7 (70.0)	54 (73.0)	n.s.
<i>Obesity, n (%)</i>	2 (20.0)	13 (17.5)	n.s.
<i>Hypertension, n (%)</i>	6 (60.0)	39 (52.7)	n.s.
<i>Type 2 diabetes mellitus, n (%)</i>	1 (10.0)	17 (22.9)	n.s.
<i>CAD and/or CVD, n (%)</i>	0 (0.0)	11 (14.8)	n.s.
<i>Cancer (previous or current), n (%)</i>	4 (40.0)	10 (13.5)	<0.05
<i>Previous VTE, n (%)</i>	1 (10.0)	2 (2.7)	n.s.
<i>Trauma or recent surgery, n (%)</i>	0 (0.0)	8 (10.8)	n.s.
<i>Acute infectious disease, n (%)</i>	84 (100.0)	74 (100.0)	n.s.
<i>Reduced mobility, n (%)</i>	10 (100.0)	62 (83.7)	n.s.
<i>Acute respiratory failure / oxygen supplementation, n (%)</i>	10 (100.0)	62 (83.7)	n.s.
<i>High flow nasal oxygen therapy or NIV</i>	6 (60.0)	9 (8.1)	<0.01
<i>Mean haemoglobin level, g/L ± SD</i>	13.5±1.8	12.8±2.1	n.s.
<i>Mean white blood cell count, 10<sup>9</sup>xL ± SD</i>	6892±3111	5688±2776	n.s.
<i>Mean platelet count, 10<sup>9</sup>xL ± SD</i>	218±106	272±121	n.s.
<i>Mean D-dimer level, µg/L ± SD</i>	6,009±8,218	3,840±6,950	n.s.
<i>- D-dimer &gt; 1,500 µg/L, n (%)</i>	8 (80.0)	38 (51.3)	n.s.
<i>- D-dimer &gt; 3,000 µg/L, n (%)</i>	6 (60.0)	17 (22.9)	<0.05
<i>Mean fibrinogen level, mg/dL ± SD</i>	560±151	491±171	n.s.

<i>Mean PT, seconds ± SD</i>	11.4±1.0	11.3±0.7	n.s.
<i>PPS, mean ± SD</i>	5.5±1.1	5.1±1.7	n.s.
<i>Mean length of hospital stay at the time of CUS, days ± SD</i>	6.2±2.3	5.7±2.2	n.s.

DVT: deep vein thrombosis; CAD: coronary artery disease; CVD; cerebrovascular disease; VTE: venous thromboembolism; NIV: non-invasive ventilation; PT: prothrombin time; PPS: Padua prediction score; CUS: compression ultrasonography